Form 4: Sensei Biotherapeutics Executive Acquires Stock Options

Stephanie Krebs, Chief Business Officer of Sensei Biotherapeutics, acquired stock options for 120,000 shares on December 20, 2024.

Summary

• Stephanie Krebs, the Chief Business Officer of Sensei Biotherapeutics, Inc., filed a Form 4 on December 23, 2024.
• The form reports a transaction that occurred on December 20, 2024, where Krebs acquired stock options for 120,000 shares.
• The exercise price of the stock options is $0.4499.
• The options vest on December 1, 2025, contingent upon continuous service with Sensei Biotherapeutics.
• The expiration date for the options is December 19, 2034.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the compensation structure and equity ownership of company executives.

Stakeholder Impact

• The acquisition of stock options by a key executive could be viewed positively by shareholders as it aligns the executive's interests with the company's long-term success.

Key Dates

Keywords

Form 4, Sensei Biotherapeutics, Stock Options, Insider Trading, Beneficial Ownership, Executive Compensation, SNSE, Stephanie Krebs